This report covers the 68 geographical markets and provides an Excel-based forecast model for the Heart Failure (HF) market through 2032.
Across the 68 markets, sales in the heart failure market were $21.6 billion in 2022, growing to $65.7 billion in 2032.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 62.5% and 51.4% of 68-market sales in 2022 and 2032, respectively.
Across the 68 markets, sales in the heart failure market were $21.6 billion in 2022, growing to $65.7 billion in 2032.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 62.5% and 51.4% of 68-market sales in 2022 and 2032, respectively.
Scope
- This publication is an expanded version of the Excel model containing the patient-based forecast sales for heart failure (HF), covered in the analyst’s report “Heart Failure: Seven -Market Drug Forecast and Market Analysis Update”, published in November 2024. In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM HF therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM HF therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Executive Summary1.1 Overview
1.2 68M summary statistics
1.3 Key 7MM events driving the 68M forecast extrapolation
2 Appendix
2.1 Abbreviations
2.2 Methodology
2.2.1 Patient-based forecast methodology
2.2.2 68M forecast extrapolation methodology
2.3 Primary research - key opinion leaders interviewed for this report
2.3.1 Key opinion leaders
2.4 Primary research - prescriber survey
2.5 About the authors
2.5.1 Analyst
2.5.2 Therapy area directors
2.5.3 Epidemiologist
2.5.4 Vice President of Disease Intelligence and Epidemiology
2.5.5 Global Head of Pharma Research, Analysis, and Competitive Intelligence
- Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen
- Bayer
- Zensun
- AstraZeneca
- Boehringer Ingelheim
- Lexicon
- CSL Vifor
- Eli Lilly
- Novartis
- Novo Nordisk
- Mesoblast
- BioCardia
- Eris LifeSciences
- Cytokinetics
